explore -WSS

explore

author：leisure time 2025-09-30 17:43:56 - browse：78

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： CDC recommends RSV monoclonal antibody for infants

hotspot

WSS

When waiting feels immoral: Empathy in the emergency department

BIO selects John Crowley as new CEO

Alnylam reports growth in sales of rare disease treatments

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

The EPA's new lead rule: How one expert crunched the numbers

Group behind ProMed defends move to subscription

focus

explore

hotspot

Cancer drug shortages should be causing more outrage

When waiting feels immoral: Empathy in the emergency department

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Florida officials tell state schools to teach AP Psychology 'in its entirety'

At least 13 dead in Texas as scorching temps continue

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Supreme Court strikes down use of affirmative action

UnitedHealth’s Optum accused of antitrust violations in California

Medical leaders decry Supreme Court decision on affirmative action

CDC director unscathed in first congressional testimony

hotspot

How to pay for weight loss drugs and save Medicare

Disappointing trial forces Pfizer to pivot on obesity medicine plans

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

H.R. 3 is the wrong path to lower drug costs

Pharma showers House GOP doctor with campaign cash

CDC recommends RSV monoclonal antibody for infants

focus

hotspot

knowledge

hotspot